ChemiCare, an innovative SME founded in December 2016, has secured $25.0 million in new funding from investors. The company is committed to the discovery and development of orphan drugs specifically for patients affected by calcium-related genetic diseases. This capital infusion marks a significant step in advancing its mission to address critical unmet medical needs within the rare disease community.
The company's core focus is on improving the quality of life for individuals suffering from rare conditions such as Duchenne Muscular Dystrophy and Tubular Aggregate Myopathies, as well as certain autoimmune disorders. ChemiCare aims to achieve this through the development of a novel therapy designed to restore abnormal intracellular calcium levels, a common pathological feature across these diverse diseases. The successful close of this funding round provides the necessary resources to accelerate these specialized therapeutic programs.
ChemiCare plans to strategically deploy the newly raised capital to further advance its pipeline of orphan drug candidates. This includes funding ongoing research and development initiatives, supporting preclinical studies, and preparing for future clinical trials. The investment will also facilitate the expansion of its scientific and operational teams, strengthening the company's capacity to bring its innovative treatments closer to patients.
This funding round underscores investor confidence in ChemiCare's scientific approach and its potential to deliver meaningful therapeutic solutions for rare diseases. The company is now well-positioned for continued growth and to make substantial progress in its efforts to develop therapies that can significantly impact the lives of patients affected by these challenging conditions.
